Scribd Logo
Upload

Welcome to Scribd!

  • 382 views

    Merck Student Case Note (Fall 14)

    Uploaded by

    Sohum Chitalia
    This document provides background information on a case study about Merck & Company evaluating a drug licensing opportunity. It discusses the substantive issues around valuing a compound before clinical trials and Merck's decision tree evaluation process. It outlines the pedagogical objectives of learning to build and use decision trees to value uncertain investments. Finally, it suggests a classroom plan involving discussing Merck's business model, building a decision tree for the drug's approval process, evaluating if Merck should license the drug and how much to pay, and calculating expected values for both companies.

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd

    Merck Student Case Note (Fall 14)

    Uploaded by

    Sohum Chitalia
    382 views2 pages
    This document provides background information on a case study about Merck & Company evaluating a drug licensing opportunity. It discusses the substantive issues around valuing a compound before clinical trials and Merck's decision tree evaluation process. It outlines the pedagogical objectives of learning to build and use decision trees to value uncertain investments. Finally, it suggests a classroom plan involving discussing Merck's business model, building a decision tree for the drug's approval process, evaluating if Merck should license the drug and how much to pay, and calculating expected values for both companies.

    Original Description:

    Merck Student Case Note

    Copyright

    © © All Rights Reserved

    Available Formats

    DOC, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document provides background information on a case study about Merck & Company evaluating a drug licensing opportunity. It discusses the substantive issues around valuing a compound before clinical trials and Merck's decision tree evaluation process. It outlines the pedagogical objectives of learning to build and use decision trees to value uncertain investments. Finally, it suggests a classroom plan involving discussing Merck's business model, building a decision tree for the drug's approval process, evaluating if Merck should license the drug and how much to pay, and calculating expected values for both companies.

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    382 views2 pages

    Merck Student Case Note (Fall 14)

    Uploaded by

    Sohum Chitalia
    This document provides background information on a case study about Merck & Company evaluating a drug licensing opportunity. It discusses the substantive issues around valuing a compound before clinical trials and Merck's decision tree evaluation process. It outlines the pedagogical objectives of learning to build and use decision trees to value uncertain investments. Finally, it suggests a classroom plan involving discussing Merck's business model, building a decision tree for the drug's approval process, evaluating if Merck should license the drug and how much to pay, and calculating expected values for both companies.

    Copyright:

    © All Rights Reserved
    Download as DOC, PDF, TXT or read online from Scribd
    Download as doc, pdf, or txt
    of 2

    C L A S S N OT E A DA P T E D F RO M H A RVA R D B U S I N E S S S C H O O L

    Merck & Company:


    Evaluating a Drug Licensing Opportunity

    Substantive Issues
    The case explores the valuation of an opportunity to license a compound before it enters clinical trials and
    describes Mercks decision tree evaluation process. It also provides information to evaluate a specific
    licensing opportunity, including the costs of the three phases of the review process, the present value of
    the revenues associated with successful outcomes, and the probability of various outcomes.

    Pedagogical Opportunities
    The primary pedagogical objective is to learn how to build and use decision trees to value uncertain
    investment outcomes. The case analysis includes:

    1. Determining how Merck generates sales/profits;

    2. Assessing the value of licensing from licensor (LAB) and licensee (Merck) perspectives;

    3. Constructing a decision tree to reflect timeline, cash flow, and probability;

    4. Calculating expected values; and

    5. Evaluating the opportunity for both companies.

    The case highlights the use of probability in assessing the value and riskiness of a project or investment.

    Suggested Classroom Plan

    1. How has Merck done as a pharmaceutical business? Is it a profitable business model? What
    are the risks and rewards associated with this model?

    Evaluate profit margins and ROIC (very large)

    Understand costs involved in developing drugs and probabilities of getting a drug from
    compound to marketing

    Realize the large value extracted once a drug is approved and under patent protection

    2. What are the potential outcomes for Davanrik?


    202-001 Teaching NoteMerck & Company: Evaluating a Drug Licensing Opportunity

    Describe FDA approval process

    Build the decision tree based on the FDA approval

    3. Should Merck license the drug? How much should it pay?

    Discuss competitive issues in bidding for the drug (e.g. is anyone willing to pay $1
    million more just to win the bid?)

    4. How much should LAB expect to receive from the proposed deal?

    Expected milestone payments

    Expected royalty payments

    Suggested Assignment Questions


    1. How has Merck been able to achieve substantial returns to capital given the large costs and
    lengthy time to develop drug?

    2. Build a decision tree that shows the cash flows and probabilities at all stages of the FDA
    approval process.

    3. Should Merck bid to license Davanrik? How much should they pay?

    4. What is the expected value of the licensing arrangement to LAB? Assume a 5% royalty fee on
    any cash flows that Merck receives from Davanrik after a successful launch.

    5. How would your analysis change if the costs of launching Davanrik for weight loss were $225
    million instead of $100 million as given in the case?

    You might also like